Clinical Trials Logo
  1. Home
  2. Primary Sjögren's Syndrome
  3. NCT04981145

The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

Primary Sjögren's Syndrome Clinical Trial

Official title:
The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome: A Multi-center, Prospective, Open Study

Clinical Trial Summary

A multi-center, prospective, open-label, randomized controlled study of efficacy and safety of Iguratimod in patients with Primary Sjögren's syndrome

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04981145
Study type Interventional
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Jing Xue
Phone 13858121751
Email xuej@zju.edu.cn
Status Recruiting
Phase Phase 4
Start date January 14, 2022
Completion date July 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03040583 - The ASSESS National Multi-center Prospective Cohort
Completed NCT01989819 - Primary Sjögren Syndrome
Completed NCT02291029 - Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome Phase 2
Terminated NCT02610543 - UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome Phase 2
Not yet recruiting NCT04975087 - The Profile of Fatigue and Discomfort - Sicca Symptoms Inventory
Completed NCT04078386 - A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome Phase 2
Recruiting NCT05087589 - Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome Phase 2
Recruiting NCT04212572 - Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease
Completed NCT02149420 - PD of VAY736 in Patients With Primary Sjögren's Syndrome Phase 2
Recruiting NCT04858464 - Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire
Recruiting NCT03003572 - Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
Completed NCT00632866 - Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome Phase 3
Completed NCT02334306 - A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome Phase 2
Completed NCT02775916 - Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome Phase 2
Completed NCT02464319 - A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome Phase 2
Terminated NCT01552681 - Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome Phase 2
Completed NCT04186871 - Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis Phase 2
Completed NCT00426543 - Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome Phase 2
Completed NCT06432101 - Acupuncture Combined With Hydroxychloroquine N/A
Completed NCT03627065 - A Study of INCB050465 in Primary Sjögren's Syndrome Phase 2